Literature DB >> 9678780

Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis.

J George1, A Afek, B Gilburd, H Levkovitz, A Shaish, I Goldberg, Y Kopolovic, G Wick, Y Shoenfeld, D Harats.   

Abstract

The role of the immune system in modulating atherosclerosis has recently been the subject of intensive research. Several previous authors have put forward a paradigm of the autoimmune process occurring in the vicinity of the plaque. Two recent studies have shown that immunization of rabbits with homologous modified low-density lipoprotein (LDL) led to suppression of atherosclerosis. In the current study we evaluated the effects of homologous malondialdehyde (MDA)-LDL immunizations on atherogenesis in apo-E-deficient mice. Two groups of female chow-diet-fed, apo-E-deficient mice (n = 10) were either immunized with homologous MDA-LDL or with phosphate buffer saline (PBS) at 2-week intervals. The mice were sacrificed 12 weeks following the primary immunization. The MDA-LDL-immunized mice were shown to develop high titers of anti-MDA-LDL antibodies. Atherosclerosis, determined by the lesion size at the aortic sinus, was significantly suppressed in the MDA-LDL-immunized mice as compared with their littermates immunized with PBS (mean area +/- S.D.; 74000 +/- 17300 microm2 versus 158000 +/- 12800 microm2; P < 0.01). No differences were found between the groups with respect to the cellular composition of the atherosclerotic plaques. The results of this study show that immunization with MDA-LDL has a protective effect in apo-E-deficient mice, and further suggests that this mouse model is suitable for studies of immunomodulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678780     DOI: 10.1016/s0021-9150(98)00015-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  57 in total

1.  IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.

Authors:  Christoph J Binder; Karsten Hartvigsen; Mi-Kyung Chang; Marina Miller; David Broide; Wulf Palinski; Linda K Curtiss; Maripat Corr; Joseph L Witztum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 2.  Intravenous immunoglobulin and atherosclerosis.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Katsumi Inoue; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

Review 4.  How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses.

Authors:  Jillian P Rhoads; Amy S Major
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

Review 5.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

Review 6.  The role of heat shock proteins in atherosclerosis.

Authors:  Georg Wick; Bojana Jakic; Maja Buszko; Marius C Wick; Cecilia Grundtman
Journal:  Nat Rev Cardiol       Date:  2014-07-15       Impact factor: 32.419

Review 7.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 8.  B cells and atherosclerosis.

Authors:  Prasad Srikakulapu; Coleen A McNamara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-17       Impact factor: 4.733

9.  Pathogenic mechanisms in systemic lupus erythematosus.

Authors:  Andras Perl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study.

Authors:  Aldar S Bourinbaiar; Vichai Jirathitikal
Journal:  Lipids Health Dis       Date:  2010-02-02       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.